Arix Bioscience plc: Management and Board Changes

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET
                               ABUSE REGULATION NO.596/2014

                               Joe Anderson appointed as CEO  

    Arix Bioscience plc (LSE: ARIX) ("Arix" or the "Company"), a global healthcare and
life science company supporting medical innovation, today announces that Chief Investment
Officer, Joe Anderson, has been reappointed as Chief Executive Officer and will re-join
the Arix Board.

    Jonathan Peacock, Executive Chairman, will become Non-Executive Chairman and Sir
Christopher Evans will retire from the Board, remaining a consultant to the Company. These
changes will take place with immediate effect, recognising the continued strong
performance of the portfolio and pipeline development.

    Jonathan Peacock, Chairman of Arix Bioscience, commented: 

    "Arix has rapidly built a strong, diverse portfolio and a top tier investment team who
continue to build value, both in our portfolio companies and for our shareholders. We have
benefited from Joe's focus as CIO over the recent months and the changes announced today
build on this and reflect a clear shift towards a leaner organisation that will continue
to drive the Company's strong growth."

    Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: 

    "Arix has a great future ahead and I appreciate this opportunity to lead the
organisation through its next stage of growth.  We have a highly talented investment team
and part of my role will be to focus resources on this aspect of our business and reduce
our cost structure elsewhere. Our core value is in the portfolio of companies we have
built, and continue to build. We have seen rapid growth in our net asset value and we are
confident that this will convert into value for shareholders, whilst the pipeline of new
opportunities remains strong. I appreciate the confidence placed in me by the Board to
lead this exceptional organisation as we continue to deliver on our strategy."

    Sir Chris Evans, commented:  

    "It has been rewarding to see Arix develop such a high-quality team and portfolio of
innovative companies, led by some of the most successful scientists and entrepreneurs in
biotech. The completion of a three-year term as a director is an appropriate time for me
to retire from the board. As a founder of the company, committed shareholder and continued
adviser I will continue to support Arix and look forward to seeing it grow under Joe's
leadership and most importantly to realise the potential value of its portfolio and
platform."

    About Arix Bioscience plc 

    Arix Bioscience plc is a global healthcare and life science company supporting medical
innovation. Headquartered in London and with an office in New York, Arix Bioscience
sources, finances and builds world class healthcare and life science businesses addressing
medical innovation at all stages of development. Operations are supported by privileged
access to breakthrough academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.

    Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For
further information, please visit http://www.arixbioscience.com



The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.